Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Status:
Terminated
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of the combination entospletinib and idelalisib in
participants with relapsed or refractory hematologic malignancies. Participants will be
enrolled who have one of the following hematological tumor types: chronic lymphocytic
leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or
indolent non-Hodgkin lymphomas (iNHL; including follicular lymphoma (FL) and
lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia [LPL/WM], small lymphocytic
lymphoma [SLL], or marginal zone lymphoma [MZL]).